Showing results (271-280 of 282) with videos related to
Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|October 4, 2022
Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective studyGilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, et al.European Journal of Cancer (Oxford, England : 1990)|March 14, 2016
Survival impact and predictive factors of axillary recurrence after sentinel biopsyGilles Houvenaeghel, Jean Marc Classe, Jean-Rémy Garbay, et al.Breast (Edinburgh, Scotland)|May 6, 2017
Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB)Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, et al.Cancer Medicine|September 21, 2022
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastasesGilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin, et al.Breast Cancer Research and Treatment|September 22, 2018
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impactGilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, et al.Gynecologie, Obstetrique, Fertilite & Senologie|December 17, 2021
[Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)]Carole Mathelin, Emmanuel Barranger, Martine Boisserie-Lacroix, et al.European Journal of Obstetrics, Gynecology, and Reproductive Biology|March 12, 2016
Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short textVincent Lavoué, Xavier Fritel, Martine Antoine, et al.Journal of Gynecology Obstetrics and Human Reproduction|November 7, 2020
Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkersCyrille Huchon, Nicolas Bourdel, Cendos Abdel Wahab, et al.European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.Journal of Gynecology Obstetrics and Human Reproduction|November 4, 2020
Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservationNicolas Bourdel, Cyrille Huchon, Cendos Abdel Wahab, et al.Pageof 29